PRAME Expression in Melanocytic Tumors.
Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ.
Am J Surg Pathol. 2018 Nov;42(11):1456-1465. doi: 10.1097/PAS.0000000000001134.
The recurrent nevus phenomenon.
Castagna RD, Stramari JM, Chemello RML.
An Bras Dermatol. 2017 Jul-Aug;92(4):531-533. doi: 10.1590/abd1806-4841.20176190.
Optimizing Q-switched lasers for melasma and acquired dermal melanoses.
Aurangabadkar SJ.
Indian J Dermatol Venereol Leprol. 2019 Jan-Feb;85(1):10-17. doi: 10.4103/ijdvl.IJDVL_1086_16.
The recurrent nevus phenomenon: a history of challenge, controversy, and discovery.
Fox JC, Reed JA, Shea CR.
Arch Pathol Lab Med. 2011 Jul;135(7):842-6. doi: 10.5858/2010-0429-RAR.1.
A Novel Punch Technique for Facial Pigmented Melanocytic Nevus.
Cao Z, Li SH, Shan XJ, Fang XG, Li H, Xu ZJ, Liang XQ, Wang ZH, Tao SJ, Lu JJ.
J Craniofac Surg. 2023 Mar-Apr 01;34(2):743-746. doi: 10.1097/SCS.0000000000009019. Epub 2022 Oct 3.
Nevus-associated melanoma: facts and controversies.
Pampena R, Lai M, Piana S, Lallas A, Pellacani G, Longo C.
G Ital Dermatol Venereol. 2020 Feb;155(1):65-75. doi: 10.23736/S0392-0488.19.06534-9.
Anti-BCL2 therapy eliminates giant congenital melanocytic nevus by senolytic and immune induction.
Wei B, Yu Q, Jin J, Zhu D, Lai B, Gu J, Yang R, Huang H, Lin H, Zhang L, Zan T, Xie F, Zhang K, Li Q.
Signal Transduct Target Ther. 2025 May 16;10(1):161. doi: 10.1038/s41392-025-02247-2.
Skin Cancer: Precancers.
Bruner P, Bashline B.
FP Essent. 2019 Jun;481:23-27.
Recurrent pigmented melanocytic nevus. A benign lesion, not to be mistaken for malignant melanoma.
Sexton M, Sexton CW.
Arch Pathol Lab Med. 1991 Feb;115(2):122-6.
Subungual Congenital Nevus with Recurrent Nevus Phenomenon.
El-Khayat RH, Rashid A, Walsh MY, McKenna KE.
Pediatr Dermatol. 2015 Sep-Oct;32(5):e197-9. doi: 10.1111/pde.12633. Epub 2015 Jul 7.
